News & Highlights
Doppel Farmaceutici proudly celebrates its thirtieth anniversary!
Founded in 1994 as a spin-off of the Hoechst Roussel Group, Doppel Farmaceutici has grown to become one of the leading European CDMOs. What began with just over 40 employees has flourished into a robust team of over 600 highly skilled professionals. Our two large manufacturing facilities, located in Cortemaggiore (PC) and Rozzano (MI), work to produce over 700 pharmaceutical products, such as HP solids [...]
Doppel Pharma CDMO Successful Revamp the Milan Sterile Department (Ampoule) in alignment with the requirements of Annex 1 GMP Guidelines.
Rozzano, 31st January 2024. Doppel Pharma CDMO is delighted to announce the successful revamping of its Sterile Department (Ampoule) at the Rozzano plant (Milan), culminating in the receipt of AIFA approval in Jan 2024. In late 2022, Doppel decided to upgrade its Milan based facility to align with stringent Annex 1 GMP Guidelines. Since then, Doppel collaborated with its customers to ensure continued availability of [...]
Doppel Pharma CDMO and its commitment towards Rare Diseases and Orphan Drugs
Doppel perspective on Orphan drugs According to the US Food and Drug Administration (FDA), an orphan drug is defined as one "intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 people in the US" (which equates to approximately 6 cases per 10,000 of its population), "or meets cost recovery provisions of the act". [...]
Doppel Pharma CDMO delivers first commercial batches of generic temperature stable Nitisinone capsules to the USA
Milan, July 4th 2022 Doppel Pharma CDMO is pleased to announce that on June 24th, it has delivered to Dipharma the first commercial batches of generic temperature stable Nitisinone capsules to be commercialized in the USA. Nitisinone is used to treat adult and pediatric patients with a confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restrictions. Since its use as the [...]
Doppel Pharma CDMO delivered the first validation & Commercial batches of Ravidasvir
On March 8th Doppel Pharma CDMO delivered the first validation & Commercial batches of Ravidasvir, to be commercialized in Malaysia for the treatment of Hepatitis C. Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage including cancer. Ravidasvir is an oral NS5A inhibitor discovered, owned and patented by Presidio Pharmaceuticals, USA. It was licensed to Egyptian drug manufacturer [...]
Meet Doppel-Dietopack in Berlin on March 30-31 at Pharma Contract Manufacturing.
Rocco Paracchini, CCO at Doppel-Dietopack, will walk you through our Technological and industrial capabilities as applicable to NCE, OTC, GX and nutraceutical (for humans and pets)